Denali Therapeutics prices IPO at $18 midpoint making it the largest biotech IPO of the year
Denali Therapeutics, a an early-stage biotech developing novel therapies for neurodegenerative diseases, raised $250 million by offering 13.9 million shares at $18, within the range of $17 to $19. At pricing, the company commands a fully diluted market value of $1.7 billion.
Printed from https://innovationblog.partners.org/denali-therapeutics-prices-ipo-18-midpoint-making-largest-biotech-ipo-year · Published 07 Nov 2018
© PARTNERS HEALTHCARE. ALL RIGHTS RESERVED